Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5954)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 22, 2022 (publication date) through Dec 4, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pathophysiology
ISSN
2150-5330
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Miura K, Maeda H, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Kotani K, Yamamoto H. Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. World J Gastrointest Pathophysiol 2022; 13(3): 96-106 [PMID: 35720167 DOI: 10.4291/wjgp.v13.i3.96] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8470/full/v13/i3/96.htm |
| Number | Citing Articles |
| 1 |
Satoshi Oeda, Yuya Seko, Hideki Hayashi, Taeang Arai, Michihiro Iwaki, Masato Yoneda, Toshihide Shima, Kazuo Notsumata, Tadashi Ikegami, Hideki Fujii, Hidenori Toyoda, Kouichi Miura, Asahiro Morishita, Kazuhito Kawata, Kengo Tomita, Miwa Kawanaka, Hiroshi Isoda, Kanji Yamaguchi, Hideaki Fukushima, Yoshihiro Kamada, Yoshio Sumida, Shinichi Aishima, Yoshito Itoh, Takeshi Okanoue, Atsushi Nakajima, Hirokazu Takahashi. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. Hepatology Research 2023; 53(6): 489 doi: 10.1111/hepr.13890
|
| 2 |
Mohammadjavad Sotoudeheian. Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings. The International Journal of Gastroenterology and Hepatology Diseases 2024; 3 doi: 10.2174/0126662906302851240604042954
|
| 3 |
Kouichi Miura, Hideki Hayashi, Yoshihiro Kamada, Hideki Fujii, Hirokazu Takahashi, Satoshi Oeda, Michihiro Iwaki, Takumi Kawaguchi, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease. Hepatology Research 2023; 53(10): 978 doi: 10.1111/hepr.13938
|
| 4 |
Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 2023; 78(1): 319 doi: 10.1002/hep.32779
|
| 5 |
Lucia Cerrito, Irene Mignini, Maria Elena Ainora, Carolina Mosoni, Antonio Gasbarrini, Maria Assunta Zocco. Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. Cancers 2023; 15(3): 637 doi: 10.3390/cancers15030637
|
| 6 |
Madalina-Gabriela Taru, Monica Lupsor-Platon. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers 2023; 15(16): 4097 doi: 10.3390/cancers15164097
|
| 7 |
Kyaw Min Tun, Nabil Noureddin, Mazen Noureddin. Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review. Clinical Liver Disease 2023; 22(3): 103 doi: 10.1097/CLD.0000000000000066
|